Brii Biosciences (2137)

Executive Summary

Brii Biosciences is a clinical-stage biotechnology company focused on addressing high unmet medical needs in infectious diseases and central nervous system (CNS) disorders, with an emphasis on reducing social stigma associated with these conditions. The company's pipeline includes novel therapies for chronic hepatitis B (HBV) and other infectious diseases, leveraging its expertise in antibodies, biologics, and small molecules. Brii's lead candidates, such as BRII-179 (a therapeutic vaccine) and BRII-835 (an siRNA therapeutic), aim to achieve functional cure for HBV, a disease affecting over 250 million people worldwide. In CNS, the company is advancing treatments for major depressive disorder and other psychiatric conditions. With a Phase 3-stage pipeline and strategic collaborations, including a partnership with Vir Biotechnology for COVID-19 antibodies, Brii is positioned to deliver transformative therapies. Recent progress includes positive Phase 2 data for BRII-179, showing enhanced immune responses, and ongoing enrollment in pivotal trials. The company's dual focus on infectious diseases and CNS, combined with its innovative approach to tackling stigmatized conditions, differentiates it in the biotech landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b data readout for BRII-179 in chronic HBV65% success
• Q4 2026Initiation of Phase 3 trial for BRII-835 (siRNA) in HBV70% success
• TBDPotential FDA Orphan Drug Designation for lead CNS asset50% success